Refine by MP, party, committee, province, or result type.

Results 1-11 of 11
Sorted by relevance | Sort by date: newest first / oldest first

Finance committee  Stephen, I can answer.

May 17th, 2021Committee meeting

Christine Jodoin

Finance committee  Just to clarify, as I said before, the mandate is that the BMC, the biologics manufacturing centre, will have a public-good mandate. It's not intended to compete with the private sector but to actually complement it, and complement it in such fashion that we'll be ready to manufa

May 17th, 2021Committee meeting

Christine Jodoin

Finance committee  No. That is right when there's a pandemic emergency. We're a gap-filler in terms of making sure that there is production capacity if it's required for cell-based biologics. Separate from that, in non-pandemic periods, we'll be focusing on pandemic preparedness, but we'll also be

May 17th, 2021Committee meeting

Christine Jodoin

Finance committee  Thank you. I just want to clear up one thing. We're not actually doing research. The facility is focused on production, so what we're going to be doing is helping to put to market drugs that the private sector right now can't on its own, either because there is a high risk of fai

May 17th, 2021Committee meeting

Christine Jodoin

Finance committee  Stephen, would you like me to answer the question?

May 17th, 2021Committee meeting

Christine Jodoin

Finance committee  We're currently assessing the right model for the future operation and governance of the facility. The endgame is that the mandate of the centre is public good and to meet pandemic emergencies and always be ready for them. With the public good perspective in mind, we are looking

May 17th, 2021Committee meeting

Christine Jodoin

Finance committee  That's correct.

May 17th, 2021Committee meeting

Christine Jodoin

Finance committee  First of all, the centre is being designed and set up with a cell-based biologics vaccine platform, one that we believe when we're going to look at collaborating with vaccine sponsors is the basis in terms of making sure that their vaccine platform is aligned with a vaccine platf

May 17th, 2021Committee meeting

Christine Jodoin

Finance committee  To clarify, the vaccine sponsor who we would contract with and produce a vaccine would need to have that platform.

May 17th, 2021Committee meeting

Christine Jodoin

Finance committee  However, in terms of partners, when you look at partners, they can be to help govern the facility itself and to operate it even with not having that experience in being the vaccine sponsor of the cell biologics. It's about your experience in operating a facility of this nature, o

May 17th, 2021Committee meeting

Christine Jodoin

Finance committee  Thank you very much, Mr. Chair. On a practical basis, to give an example of the interpretation, under this current authority NRC is able to do R and D and production of an experimental nature. Right now, for example, our human health therapeutics research centre can do productio

May 17th, 2021Committee meeting

Christine Jodoin